# Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML

> **NCT02891278** · PHASE1 · COMPLETED · sponsor: **Columbia University** · enrollment: 6 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Sertraline
- **DRUG:** Cytosine arabinoside
- **PROCEDURE:** allogeneic stem cell transplantation

## Key facts

- **NCT ID:** NCT02891278
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-11
- **Primary completion:** 2020-11-17
- **Final completion:** 2020-11-17
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02891278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02891278, "Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02891278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*